Summary of FDA antibody-mediated rejection workshop

American Journal of Transplantation

Volumn 11, Issue 5, 2011, Pages 896-906

  Archdeacon, P ^a   Chan, M ^a   Neuland, C ^a   Velidedeoglu, E ^a   Meyer, J ^a   Tracy, L ^a   Cavaille Coll, M ^a   Bala, S ^a   Hernandez, A ^a   Albrecht, R ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

A ntibody mediated rejection; clinical trials; evidence based medicine; regulatory issues; surrogate endpoints; transplantation research

Indexed keywords

ANTIBODY; BORTEZOMIB; CALCINEURIN INHIBITOR; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ECULIZUMAB; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ANTIBODY DETECTION; CONFERENCE PAPER; DESENSITIZATION; DRUG MEGADOSE; FOOD AND DRUG ADMINISTRATION; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; NONHUMAN; ORGAN DONOR; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ANIMALS; ANTIBODIES; CLINICAL TRIALS AS TOPIC; GRAFT REJECTION; HLA ANTIGENS; HUMANS; MODELS, ANIMAL; ORGAN TRANSPLANTATION; PROGNOSIS; RESEARCH DESIGN; RISK; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79955539062     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03525.x     Document Type: Conference Paper

References (46)

1. Halloran PF, Wadgymar A, Ritchie S, Falk J, Solez K, Srinivasa NS,. The significance of the anti-class I antibody response: I. Clinical and pathologic features of anti-class I-mediated rejection. Transplantation 1990; 49: 85-91. (Pubitemid 20051591)
2. Moll S, Pascual M,. Humoral rejection of organ allografts. Am J Transplant 2005; 5: 2611-2618.
3. Amico P, Honger G, Mayr M, Steiger J, Hopfer H, Schaub S,. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 2009; 87: 1681-1688.
4. Gloor JM, Winters JL, Cornell LD, et al,. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 2010; 10: 582-589.
5. Lefaucheur C, Nochy D, Hill GS, et al,. Determinants of poor graft outcome in patients with antibody-mediated acute rejection. Am J Transplant 2007; 7: 832-841. (Pubitemid 46481179)
6. Einecke G, Sis B, Reeve J, et al,. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520-2531.
7. Gaston RS, Cecka JM, Kasiske BL, et al,. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68-74.
8. Issues in the development of medical products for the prophylaxis and/or treatment of acute antibody mediated rejection in kidney transplant recipients: Public Workshop. Fed Reg 2010; 75: 32490-32491.
9. Lefaucheur C, Suberbielle-Boissel C, Hill GS, et al,. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Contrib Nephrol 2009; 162: 1-12.
10. Lefaucheur C, Loupy A, Hill GS, et al,. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398-1406.
11. Hidalgo LG, Campbell PM, Sis B, et al,. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009; 9: 2532-2541.
12. Nickerson P, Blydt-Hansen T, Rush D, et al,. De Novo donor specific antibody (DSA) is associated with decreased kidney graft survival and subclinical antibody mediated rejection [abstract]. Am J Transplant 2010; 10: 284.
13. Bray RA, Gebel HM,. Strategies for human leukocyte antigen antibody detection. Curr Opin Organ Transplant 2009; 14: 392-397.
14. Kolber-Simonds D, Lai L, Watt SR, et al,. Production of alpha-1,3-galactosyltransferase null pigs by means of nuclear transfer with fibroblasts bearing loss of heterozygosity mutations. Proc Natl Acad Sci USA 2004; 101: 7335-7340. (Pubitemid 38638033)
15. Nozaki T, Amano H, Bickerstaff A, et al,. Antibody-mediated rejection of cardiac allografts in CCR5-deficient recipients. J Immunol 2007; 179: 5238-5245.
16. Torrealba JR, Fernandez LA, Kanmaz T, et al,. Immunotoxin-treated rhesus monkeys: a model for renal allograft chronic rejection. Transplantation 2003; 76: 524-530. (Pubitemid 37013257)
17. Racusen LC, Colvin RB, Solez K, et al,. Antibody-mediated rejection criteria-an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714. (Pubitemid 36745243)
18. Seemayer CA, Gaspert A, Nickeleit V, Mihatsch MJ,. C4d staining of renal allograft biopsies: A comparative analysis of different staining techniques. Nephrol Dial Transplant 2007; 22: 568-576. (Pubitemid 46189903)
19. Sis B, Jhangri GS, Bunnag S, Allanach K, Kaplan B, Halloran PF,. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009; 9: 2312-2323.
20. Racusen LC, Haas M,. Antibody-mediated rejection in renal allografts: Lessons from pathology. Clin J Am Soc Nephrol 2006; 1: 415-420.
21. Lobo PI, Spencer CE, Stevenson WC, Pruett TL,. Evidence demonstrating poor kidney graft survival when acute rejections are associated with IgG donor-specific lymphocytotoxin. Transplantation 1995; 59: 357-360.
22. Jordan SC, Quartel AW, Czer LS, et al,. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998; 66: 800-805.
23. Pascual M, Saidman S, Tolkoff-Rubin N, et al,. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation 1998; 66: 1460-1464. (Pubitemid 29014024)
24. Kaplan B, Gangemi A, Thielke J, Oberholzer J, Sankary H, Benedetti E,. Successful rescue of refractory, severe antibody mediated rejection with splenectomy. Transplantation 2007; 83: 99-100. (Pubitemid 46104982)
25. Locke JE, Zachary AA, Haas M, et al,. The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant 2007; 7: 842-846. (Pubitemid 46481192)
26. Stegmayr B, Ptak J, Wikstrom B, et al,. World apheresis registry 2003-2007 data. Transfus Apher Sci 2008; 39: 247-254.
27. Accelerated Approval Regulations: Subpart H for drugs (21 CFR 314.510) and Subpart E for biologics (21 CFR 601.41), (2010).
28. Cantarovich M, Paraskevas S, Chaudhury P, Baran D, Keith D, Hassanian M,. Estimated GFR after treatment of acute rejection: A surrogate marker for long-term graft survival after kidney transplantation [abstract]. Transplantation 2008; 86: 169.
29. Lachmann N, Terasaki PI, Budde K, et al,. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009; 87: 1505-1513.
30. Burns JM, Cornell LD, Perry DK, et al,. Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. Am J Transplant 2008; 8: 2684-2694.
31. Everly MJ, Rebellato LM, Ozawa M, et al,. Beyond histology: Lowering human leukocyte antigen antibody to improve renal allograft survival in acute rejection. Transplantation 2010; 89: 962-977.
32. Gloor JM, Cosio FG, Rea DJ, et al,. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006; 6: 1841-1847. (Pubitemid 44024955)
33. Regele H, Bohmig GA, Habicht A, et al,. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: A contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002; 13: 2371-2380. (Pubitemid 34925248)
34. Kieran N, Wang X, Perkins J, et al,. Combination of peritubular c4d and transplant glomerulopathy predicts late renal allograft failure. J Am Soc Nephrol 2009; 20: 2260-2268.
35. Smith RN, Kawai T, Boskovic S, et al,. Four stages and lack of stable accommodation in chronic alloantibody-mediated renal allograft rejection in Cynomolgus monkeys. Am J Transplant 2008; 8: 1662-1672.
36. Crespo M, Pascual M, Tolkoff-Rubin N, et al,. Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. Transplantation 2001; 71: 652-658. (Pubitemid 32268068)
37. Montgomery RA, Zachary AA, Racusen LC, et al,. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887-895.
38. Rocha PN, Butterly DW, Greenberg A, et al,. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 2003; 75: 1490-1495. (Pubitemid 36597283)
39. Shah A, Nadasdy T, Arend L, et al,. Treatment of C4d-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin. Transplantation 2004; 77: 1399-1405. (Pubitemid 38668435)
40. Becker YT, Becker BN, Pirsch JD, Sollinger HW,. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004; 4: 996-1001. (Pubitemid 38745599)
41. Faguer S, Kamar N, Guilbeaud-Frugier C, et al,. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 2007; 83: 1277-1280. (Pubitemid 46743692)
42. Bohmig GA, Wahrmann M, Regele H, et al,. Immunoadsorption in severe C4d-positive acute kidney allograft rejection: A randomized controlled trial. Am J Transplant 2007; 7: 117-1121.
43. Everly MJ, Everly JJ, Susskind B, et al,. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008; 86: 1754-1761.
44. Walsh RC, Everly JJ, Brailey P, et al,. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 2010; 89: 277-284.
45. Lefaucheur C, Nochy D, Andrade J, et al,. Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 2009; 9: 1099-1107.
46. Brown CM, Abraham KA, O'Kelly P, Conlon PJ, Walshe JJ,. Long-term experience of plasmapheresis in antibody-mediated rejection in renal transplantation. Transplant Proc 2009; 41: 3690-3692.